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Abstract: Allergy transfer upon solid organ transplantation has been reported in the literature although
only few data are available as to the frequency, significance and management of these cases. Based on a
review of 577 consecutive deceased donors from the Swisstransplant Donor-Registry, three cases (0.5%)
of fatal anaphylaxis were identified, two because of peanut and one of wasp allergy. The sera of all three
donors and their ten paired recipients, prospectively collected before and after transplantation from the
Swiss-Transplant-Cohort-Study, were retrospectively processed using a commercial protein microarray
fluorescent test. As early as five days post-transplantation, newly acquired peanut-specific IgE were
transiently detected from one donor to three recipients, of whom one liver and lung recipients developed
grade III anaphylaxis. Yet, to define how allergy testing should be performed in transplant recipients and
to better understand the impact of immunosuppressive therapy on IgE sensitization, we prospectively
studied five atopic living-donor kidney recipients. All pollen-specific IgE and >90% of skin prick tests
remained positive 7 days and 3 months after transplantation indicating that early diagnosis of donor-
derived IgE sensitization is possible. Importantly, we propose recommendations with respect to safety
for recipients undergoing solid-organ transplantation from donors with a history of fatal anaphylaxis.
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Abstract 
Allergy transfer upon solid organ transplantation has been reported in the literature although only 
few data are available as to the frequency, significance and management of these cases. 
Based on a review of 577 consecutive deceased donors from the Swisstransplant Donor-Registry, 
three cases (0.5%) of fatal anaphylaxis were identified, two because of peanut and one of wasp 
allergy. The sera of all three donors and their ten paired recipients, prospectively collected before 
and after transplantation from the Swiss-Transplant-Cohort-Study, were retrospectively processed 
using a commercial protein microarray fluorescent test. As early as five days post-transplantation, 
newly acquired peanut-specific IgE were transiently detected from one donor to three recipients, 
of whom one liver and lung recipients developed grade III anaphylaxis. Yet, to define how allergy 
testing should be performed in transplant recipients and to better understand the impact of 
immunosuppressive therapy on IgE sensitization, we prospectively studied five atopic living-
donor kidney recipients. All pollen-specific IgE and >90% of skin prick tests remained positive 7 
days and 3 months after transplantation indicating that early diagnosis of donor-derived IgE 
sensitization is possible. Importantly, we propose recommendations with respect to safety for 
recipients undergoing solid-organ transplantation from donors with a history of fatal anaphylaxis. 
1. Introduction
Anaphylaxis is a frequent cause of hospitalization with an estimated annual fatality rate of 
approximately 0.5 per 1’000’000. Food allergy being the most common cause for anaphylaxis in 
children and young adults, death due to food allergy was found in about 25% of the reported 
patients (1). Peanuts or tree-nuts were the causative allergens in more than 70% of the cases in 
which the responsible allergen was identified. Other allergens frequently involved in fatal 
anaphylaxis are fish, milk and egg but also bee and wasp venom, and drugs (1).
The first cases of transplant associated-allergy transfer were reported after hematopoietic stem cell 
transplantation, likely caused by IgE-specific B cells or T helper type 2  cells that were co-
transferred with hematopoietic stem and progenitor cells (2). Subsequently, cases of allergy 
transfer were also described after solid organ transplantation (SOT), predominantly after liver, 
lung or combined pancreas-kidney transplantation (Table 1) (3–11). Only very few data are 
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In addition, the impact of immunosuppression on IgE sensitization is poorly understood. The 
objectives of this study were: (1) to identify the frequency and significance of allergy transfer 
based on retrospective analysis from the Swiss-transplant-Donor Registry and the Swiss-
Transplant-Cohort-Study (STCS); (2) to evaluate if allergy testing is feasible early after solid 
organ transplantation; (3) to make recommendations for the diagnosis and management of allergy 
transplant after SOT. 
2. Material and methods. 
2.1 Donor-to-recipient IgE transfer 
We retrospectively reviewed the data of 577 consecutive deceased donors from the 
Swisstransplant Donor-Registry (from January 2012 to May 2017) and identified three donors 
who died of anaphylaxis. In this registry, the individual history of severe allergy was not recorded.  
We then collected the prospectively stored sera of each donor-paired recipient from the STCS 
(Table 2) (12), a prospective multicenter cohort including all SOT performed in Switzerland as of 
May 2008. Sera of the recipients are prospectively collected at baseline (day of transplantation), 6 
and 12 months after transplantation. In addition, sera were individually collected throughout the 
different centers at specific time points after transplantation. To assess the IgE profile of the donor 
and recipient’s sera, a commercial protein microarray fluorescent test bearing recombinant 
allergen molecules (ISAC™, ThermoFisher Scientific) was used. ISAC standardized units (ISU-E) 
were assessed using a cut-off value defined at 0.35 ISU. All recipients gave written informed 
consent for participation. Local ethics IRB committee (ID 2017-1058, CCER-GE) and 
Swisstransplant approved the study.
2.2 Immunosuppression and IgE sensitization
Skin prick tests (SPT), specific IgE values and clinical symptoms were monitored in five 
adult living-donor kidney transplant recipients suffering from symptomatic allergic rhino-
conjunctivitis between November 2016 and August 2018. The rhino-conjunctivitis score was 
based on the subject’s nasal (runny nose, blocked nose, sneezing, itchy nose) and eye symptoms 
(gritty feeling/red/itchy eye and watery eye) using a 3-point scale (none=0, slight symptoms=1, 
moderate symptoms=2, and severe symptoms=3) for the six symptom classes. All recipients gave 
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3. Results
3.1 Donor case 1
One young organ donor died of peanut-allergy-induced anaphylaxis leading to cardiac 
arrest with subsequent brain death. Upon admission, tryptase was > 100ng/ml (normal results: 
<10ng/ml). With the consent of the relatives, the heart, lungs, liver and kidneys were procured for 
transplantation. The liver was further split and transplanted into two recipients (Figure 1A).  On 
post-transplant follow-up, the kidney of one recipient had to be explanted within the first week 
post-transplant because of multiple surgical complications and the patient was subsequently 
excluded from the analysis. Recombinant peanut-specific IgE known to be major elicitors of 
clinically relevant allergy (13) could be detected in the donor (Ara h1: 42 ISU-E, Ara h2: 85 ISU-
E, Ara h3: 36 ISU-E, and Ara h6: 61 ISU-E), and in both liver (LiverR1, LiverSplitR2) and lung 
recipients (LungR3), but neither in the kidney nor in the heart recipients of the same donor (Figure 
1B-C).
In the case of LiverR1, an inadvertent oral ingestion of two peanuts on POD 11 resulted in 
stomach pain, vomiting and transient dyspnea. LungR3 underwent an oral challenge on POD 30 
with a starting dose of 6mg peanut (=1.5 mg peanut protein ED05). After the fifth dose, the patient 
developed urticaria, acute asthma and stomach pain. The oral challenge was negative in LiverR2. 
However, the test was performed nine months after transplantation when peanut-specific IgE were 
not detectable anymore in the patient’s sera.
LiverR1 and LungR3 responded to treatment with antihistamines, glucocorticoids and 
inhaled salbutamol. Two years after transplantation, an oral challenge with peanuts was well 
tolerated by recipient LiverR1 after SPT had become negative, whereas LungR3 refused a repeat 
oral challenge. Of note, recipients with de novo transferred-IgE were atopic as defined here by the 
presence of specific IgE against, pollen, animal dander or house dusts mites (Figure 1D). These 
data indicated that de-novo occurrence of specific IgE to recombinant peanut allergen IgE (Ara h1, 
2, 3 and 6) may predict allergy transfer in SOT. 
3.2 Donor cases 2 
The second donor had a history of wasp allergy and developed cardiac arrest after a wasp 
sting despite of the self-application of epinephrine. Analysis of the sera upon admission showed a 
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recombinant wasp venom allergens (rVes v5 1.1 ISU-E, wasp IgE negative). An ISAC performed 
in both the donor and two recipients (kidney and lung) did not show any IgE transfer. In this case, 
failure to document an elevation of the tryptase or specific IgEs does not exclude the diagnosis of 
IgE-mediated anaphylaxis in light of the personal history (14, 15) although a non-IgE mediated-
anaphylaxis (mast cell liberation, IgG- or complemented-mediated) might be possible. Overall, 
these data suggest that if the exact nature of an allergy is not appropriately documented in the 
donor, the pre-test probability of identifying allergy transfer is likely reduced.
3.3 Donor cases 3
The third donor had an anaphylactic reaction with cardiac arrest supposedly mediated by 
peanut ingestion. On admission, tryptase was elevated (38.1 ng/ml) whereas serum IgE (measured 
by UniCAP™, ThermoFisher) to peanut (3,04 kUI/l), hazelnut (6,74 kUI/l), almond (1,14 kUI/l), 
cashew nut (1,27 kU/l) and pistachio (3,24 UI/l) were only moderately elevated. Interestingly, in 
the sera of the donor a high level of nAct d1 (actindin) was found, a serological marker which can 
be associated with severe allergic reactions to kiwi (16). However, the serological analysis of the 
three recipients of this donor, i.e pancreas-kidney, heart-kidney, and liver showed no peanut and 
kiwi IgE at six months’ post-transplantation. Interestingly, the donor was also highly sensitized to 
animals (rCanf1:87 ISU-E, rCanf5 46 ISU-E, rEqu c1: 19 ISU-E), ash/olive pollen (rOle e1 29 
ISU-E l) and mites (rDerp1 36 ISU-E), in contrast to the recipients where none of these specific 
IgE were detected. Notably, none of the recipients was atopic either (based on serology). In this 
case, a kiwi-induced anaphylaxis could not be excluded emphasizing the importance of assessing 
the allergy profile of the donor at the time of transplantation.  
3.4 Diagnosis of IgE sensitization early after transplantation
So far, it remains unclear whether IgE and allergy transfer are affected by the  
immunosuppressive therapy. Also, the important question whether detection of IgE sensitization is 
possible early after transplantation is unanswered (17). The  overall number of IgE sensitizations 
of all five atopic recipients remained unchanged within the first 6 months after transplantation 
(Figure 1E). We therefore decided to study the impact of immunosuppressive therapy on IgE and 
allergy maintenance. To this purpose, we performed a prospective follow-up analysis on five 
symptomatic patients with pre-existing allergic rhino-conjunctivitis undergoing living donor 
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transplantation. All five patients received a standard induction and maintenance 
immunosuppressive therapy with basiliximab and methylprednisolone followed by oral 
tacrolimus, prednisone and mycophenolate mofetil (Figure 2A). SPT and serological analysis were 
performed before, seven days and 3 months after transplantation, respectively. Surprisingly, the 
immunosuppressive therapy only moderately affected the skin tests (SPT) results seven days after 
transplantation (Figure 2B-C) and had no impact on the specific and total IgE levels (Figure 2D-
E). Twenty-two of twenty-three and 21/23 of SPT remained positive seven days and three months 
after transplantation respectively. Finally, the rhino-conjunctivitis score (daily nasal and eye 
symptoms using a 4-point scale: none, mild, moderate, and severe) before and three months after 
transplantation did not show a significant improvement (Figure 2F). Overall, these results indicate 
that IgE sensitization is weakly affected early after transplantation and can be detected based on 
SPT and IgE serologies despite immunosuppressive therapy.
4. Discussion
4.1 Mechanisms of allergy transfe
As reviewed in the literature (Table 1), allergy transfer was demonstrated after liver, lung, 
and pancreas transplantation, but so far not in heart and kidney recipients alone. One could 
therefore speculate that allergy transfer is a donor organ-specific phenomenon. Interestingly, in the 
case series reported by Berry et al, allergy transfer occurred in the pancreas-kidney recipient but 
not in the recipient of an isolated kidney, possibly because of the co-transplantation of a small 
bowel portion together with the pancreas (6). These data suggest that kidney and heart tissues are 
less likely to contain sufficient IgG1-memory B-cells (IgG1-MBcs) and/or IgE-producing B-cells 
(IgE-Bcs) (Figure 3). Thus, the majority of allergen-specific IgE in the blood does not originate 
from blood-derived B/plasma cells suggesting that local IgE production in tissues is indeed the 
major source of allergen-specific IgE (18).  Furthermore, it is known that persistence of some 
tissue resident T cells clones can be organ-specific, i.e. influenza specific CD8+T cells are 
predominantly found in the lungs whereas hepatitis-specific CD8 are predominantly found in the 
liver (19). The fact that plasmatic IgE can be detected as early as 24 hours after transplantation 
and that it persists up to several months/years suggests that the primary mechanism lies in the 
transfer of  IgE-producing cells rather than in passive transfer of IgE only, as the half-life of free 
circulating IgE is known to be only two to four days (20). Interestingly, several groups reported 
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transferred and secondarily binds to mastocytes, which increases IgE half-life (Table 1, Figure 3) 
(21). Thus, SPT and IgE serological analysis can be complementary in the diagnosis of allergy 
transfer.
4.2 Persistence of sensitization and allergy 
The persistence of sensitization after allergy transfer in SOT recipients over time is poorly 
understood. In our series, LiverR1 had detectable IgE for over 393 days (Figure 1C) which turned 
negative 2 years after transplantation, whereas in LiverSplitR2 peanut-specific IgE were positive 
for less than 53 days. LiverR1 received an extended liver graft and eventually increased number of 
passenger leukocytes, but on the other hand LiverSplitR2 has never been exposed to peanut before 
peanut-specific IgE levels turned negative. Thus, early exposure to allergen after SOT may lead to 
expansion of IgE-Bcs, or alternatively switch from IgG1-MBcs into IgE producing cells (22) 
(Figure 3). 
Interestingly, in lung transplant recipients, allergy transfer seems to persist longer than in 
liver recipients (Table1) probably due to the high amount of immune cells in human lung tissue 
including 100’000 of mast cells per gram of tissue (21). Khalid et al. reported a lung recipient who 
developed an acute asthma attack without other symptoms of anaphylaxis seven years after 
transplantation upon exposure to peanuts with negative SPT and negative peanut-specific IgE 
(Table1, Series 8). This corroborates older data showing that previously non-asthmatic recipients 
can become asthmatic after lung transplantation from mildly asthmatic donors (23). 
Finally, results from hematopoietic stem cell transplantation suggest that matured Th2-like 
cells or hematopoietic progenitor stem cells are also sufficient to induce and maintain long-term 
allergy transfer for (more) than 16 years (24).  Thus, duration and persistence of the transferred 
allergy status over time may depend on the organ transplanted and mechanisms of allergy transfer. 
4.3 Immunosuppression and allergy
Importantly, our data and that of others (Table 1) indicate that the conventional 
immunosuppression does not affect IgE-sensitization. This finding is not surprising since donor-
specific IgG-producing B cells can mediate acute and/or chronic allograft rejection, two conditions 
which are associated with limited response to therapy despite several lines of treatments (25, 26). 
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hemolysis or idiopathic thrombocytopenic purpura within the first two weeks after liver 
transplantation (27–29). 
It has been previously shown that sensitization and allergy symptoms in children after SOT 
might not be controlled by immunosuppression. On the contrary, the rate of sensitization in 
patients treated with tacrolimus was even increased (30, 31). Our data from the five living-donor 
kidney recipients with allergic rhino-conjunctivitis support the observation that diagnosis of 
donor-derived IgE sensitization based on IgE and SPT is possible early after transplantation 
despite an immunosuppressive regimen based on basiliximab induction, 
methylprednisolone/prednisone, tacrolimus and mycophenolate mofetil as maintenance treatment. 
Further studies assessing the impact on SPT and IgE of other commonly used immunosuppressive 
drugs, i.e thymoglobulin, azathioprine or rapamycin are warranted. 
4.4 Management and patient care
In summary, increased attention has to be given to the risk of allergy transfer after SOT. 
Unfortunately, the exact frequency and clinical consequences of IgE transfer remains poorly 
understood as the allergy/atopy status of the donors and recipients are rarely consequently 
assessed. This is a limitation of the present study, as we focused on donors with fatal anaphylaxis 
only. In cases of possible or probable fatal anaphylaxis, specific IgE testing in the donor should be 
performed as one of the first-line investigations to evaluate the possibility of allergy transfer 
(Figure 4).  As donors with a history of severe allergy may die of other reasons than anaphylaxis 
(Table 1), we would also suggest to carefully explore history of severe allergic reaction to food, 
hymenoptera venom and drugs with the family of the donor, albeit concise recommendations in 
this setting are difficult to implement in light of our current knowledge.
Regarding the recipients of organ donors with fatal anaphylaxis, those receiving a liver, 
lung and pancreas should be closely monitored after transplantation. Furthermore, we encourage 
to initially check the atopic status of the recipient by the using a qualitative serological screening 
test (e.g Phadiatop) and measurement of total IgE, as atopic patients may be at a higher risk of 
allergy transfer. Strict avoidance of eliciting food allergens is strongly advised and emergency 
medication (including self-injectable epinephrine device) should be prescribed. A detailed allergy 
work-up as well as follow-up of the sensitization profile is important. In case of donor-derived IgE 
sensitization transfer, SPT and IgE should be monitored over time. Food challenge should only be 
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specific-IgEs when IgEs to recombinant allergens known to induce severe anaphylaxis are below 
the threshold level. 
In conclusion, we demonstrate that SPT and IgE analysis can be performed as early as 7 
days after transplantation. Therefore, postponing investigation the allergological investigation is 
unnecessary. Prescription of anti-histamines should be omitted in any case seven days prior to SPT 
as per standard recommendation (17). Finally, good medical practice would include a food 
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Figure legends
Figure 1: Allergy transfer analysis in donor and recipients. A. Overview of 3 series of donors who 
died because of fatal anaphylaxis. Green charts show patients with IgE transfer and red charts 
patients without detectable IgE transfer. Dashed lines highlights recipients with positive oral 
challenge. § shows atopic recipients. Atopic status was assessed by the presence of specific IgE 
against, pollen, animal dander or house dusts mites using commercial protein microarray bearing 
recombinant allergenic molecules (ISAC).  B. Donors sera analysis with ISAC. Green 
recombinant IgE highlights those who were transferred into recipients (left Y axis). Yellow bars 
(right Y axis) represents the tryptase (ng/ml) measured in donors during their hospitalization.  
IgE follow-up over time in recipients (liver recipient 1 (LiverR1), liver recipient 2 (LiverSplitR2), 
lung recipient (LungR3)) of series 1 compared to donor. D. Percentage of atopic recipients with or 
without IgE transfer. E. Absolute number of sensitizations before and 6 months after 
transplantation in all atopic recipients (series1-3). 
Figure 2: Allergy persistence in five symptomatic atopic patients. A. Immunosuppression protocol 
of the five recipients over time. B. Representative skin prick test results 7 days after 
transplantation in one of the recipients. . Areas in mm2 of the positive skin prick tests the day 
before transplantation and 7 and 90 days after transplantation. D. Level of total IgE over time (day 
before transplantation, 7 and 90 days after transplantation) E. Level of recombinant IgE over time 
(day before transplantation, 7 and 90 days after transplantation). F. Rhino-conjunctivitis 
symptoms score before and 90 days after transplantation. 
Figure 3: Mechanisms for allergy transfer. Abbreviations: (IgE) Immunoglobulin E. (MC) 
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Figure  4: Recommendation for patient management in case of solid organ transplantation from 
donors who died because of fatal anaphylaxis. 
Table legend
Table 1: Systematic review of the literature for allergy transfer. Abbreviations: POD (post-
operative day), POW (post-operative week).
Table 2: Baseline clinical data of the recipients. Atopic status was assessed by the presence of 
specific IgE against, pollen, animal dander or house dusts mites using commercial protein 
microarray bearing recombinant allergenic molecules (ISAC).  Abbreviations: (MMF) 
Mycophenolate mofetil; (MPA) Mycophenolic acid; (TAC) Tacrolimus; (CsA) Cyclosporine. 
(TX) Transplantation 
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